Beyond The Abstract: Urology

IO & Prostate cancer: When Two Phase III Trials Answer the Same Question—and the Answer Is “No”

Spoiler alert: no room for checkpoint inhibitors in metastatic prostate cancer!

1 hr ago • Dries Develtere

TALAPRO-2: a strong trial, a real survival gain, but at the cost of high toxicity

A strong case for intensification, without closing the sequencing debate

Jan 2 • Dries Develtere

1

3

1

A First Year of Looking Beyond the Abstract: 2025 in Urology Trials

Looking back at 2025, one pattern stands out: a year full of anticipation, but light on true game-changers.

Jan 1 • Dries Develtere

December 2025

CREST Trial: Positivity by Redesign, Ethical Concerns in Treatment Allocation, and Industry-Controlled Safety Signals

Another "Game Changer" with major limitations

Dec 10, 2025 • Dries Develtere

1

1

CAPItello-281 phase III study: Not a Game Changer at all in prostate cancer treatment

A closer look at why capivasertib fails to deliver meaningful benefit in PTEN-deficient mHSPC

Dec 4, 2025 • Dries Develtere

1

2

November 2025

SEXTANT-PRO: A Clean Non-Inferiority Trial With Practice-Changing Potential

In MRI-positive patients, accuracy may not come from more sampling — but from smarter sampling.

Nov 29, 2025 • Dries Develtere

Metformin in Active Surveillance: A Simple Question, a Clear Answer

Spoiler alert: negative results are also results, which lead to progress

Nov 8, 2025 • Dries Develtere

1

Urothelial Cancer Breakthrough: Beyond the RC48-C016 Abstract

Disitamab Vedotin + Toripalimab in HER2-Expressing Advanced Urothelial Cancer - New England Journal of Medicine, October 2025

Nov 5, 2025 • Dries Develtere

2

October 2025

The AMPLITUDE Trial — PARP Inhibition Moves Upstream in HRR-Deficient mCSPC

Johnson & Johnson want Niraparib in the hormone-sensitive BRCA-altered prostate cancer setting based on PFS — efficacy signal, but fundamental design…

Oct 28, 2025 • Dries Develtere

EMBARK Final Results: OS benefit with a catch

Do we have enough data to defend the use of Enzalutamide in the Biochemical Recurrence setting?

Oct 20, 2025 • Dries Develtere

1

POTOMAC: A Closer Look at Durvalumab in BCG-Naive NMIBC

The POTOMAC trial results are out — presented at ESMO and now published in The Lancet.

Oct 18, 2025 • Dries Develtere

2

1

1

CONTACT-02: Limited clinical benefit and suboptimal control group.

When the endpoint and control arm weaken the conclusion

Oct 14, 2025 • Dries Develtere